Co-crystals have emerged over recent years as a promising way to modify the properties of a compound through judicious selection of a co-former molecule. Hence they provide attractive new and alternative solid forms particularly in pharmaceutical applications, using active pharmaceutical ingredients (APIs). Traditional design strategies utilise supramolecular synthons facilitated by strong hydrogen bonding interactions, chosen depending upon the functional groups present in the molecule of interest. If no, minimal, or only restricted (through sterics) functional groups are present on a molecule the design is more challenging. Studies on such molecules are limited and primarily use trial and error-based methods for co-former selection hence, an alternative method is required.
